Generic Name and Formulations:
Brinzolamide 1%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for AZOPT:
Open-angle glaucoma. Ocular hypertension.
1 drop 3 times daily.
Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Discontinue if serious systemic, ocular (eg, conjunctivitis, lid edema), or hypersensitivity reactions occur. Soft contact lenses (remove; may reinsert 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers: not recommended.
Carbonic anhydrase inhibitor (sulfonamide).
Concomitant oral carbonic anhydrase inhibitors: not recommended. Separate administration of other oph drugs by ≥10 minutes.
Blurred vision, bitter/sour taste, blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia; ocular discharge, discomfort, or itch; keratitis, rhinitis.
Susp—2.5mL, 5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Whole Genome Sequencing Use in Predicting TB Resistance
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Interferon Alfa May Decrease the Incidence of Chronic HCV Infection
- Predicative Factors for Relapse in Adult Bacterial Osteomyelitis
- Supply Updates Announced for Recombivax HBV Vaccines
- Point-of-Care Testing Methods Compared for Influenza Detection
- Success With DAA for Hepatitis C Prior to Stem Cell Transplant